Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA.
Annu Rev Med. 2012;63:171-83. doi: 10.1146/annurev-med-050410-105655. Epub 2011 Oct 27.
Metastatic melanoma has historically been one of the most treatment-refractory types of cancer. Recent headway has been made in understanding the genetic underpinnings of this cancer. A subset of oncogenic events is amenable to targeting with drug therapy. BRAF-targeted therapies represent the first major breakthrough in systemic therapy for melanoma leveraging the new genetic knowledge. Ongoing translational research seeks to identify the most scientifically rational combination treatment strategies to build on single-agent targeted therapy.
转移性黑色素瘤一直以来都是治疗最棘手的癌症类型之一。近年来，人们在理解这种癌症的遗传基础方面取得了进展。一部分致癌事件可以通过药物治疗来靶向治疗。BRAF 靶向疗法是利用新的遗传知识在黑色素瘤的全身治疗方面取得的第一个重大突破。正在进行的转化研究旨在确定最具科学合理性的联合治疗策略，以建立在单一靶向治疗的基础上。
